A rationale for testing combination treatments with HDAC and PARP inhibition in cancers not sensitive to PARP inhibitor monotherapy has been defined, given that HDAC inhibition has been shown to be able to induce pharmacologic “BRCAness” in cancer cells with proficient DNA repair activity [51,52]. This evidence concerns the gene HDAC9 and cancer.